Correction
==========

In the published work \[[@B1]\], Figure three A panels e and f and Figure four B (Figure [1](#F1){ref-type="fig"}B here) panels b and f represent the same types of samples in two different experiments, i.e., CIP4 siRNA-transfected myocytes cultured in the absence and presence of phenylephrine, respectively. However, in the original version of Rusconi, et al. \[[@B1]\], the panels in Figure three A e and f were unintentionally duplicated in the panels in Figure four B (Figure [1](#F1){ref-type="fig"}B here) b and f, respectively. In this correction, a new Figure four (Figure [1](#F1){ref-type="fig"} here) is provided with different panels for figure four B (Figure [1](#F1){ref-type="fig"}B) b and f. The interpretation and conclusion of the depicted experiments remain the same.

![**The CIP4 FCH domain is important for neonatal rat ventricular myocyte hypertrophy.** Neonatal rat ventricular myocytes were transfected with control or CIP4 siRNA and then infected with adenovirus expressing myc-tagged CIP4 WT or ΔFCH protein. Myocytes were stimulated with 10 μM PE for two days as indicated. **A**. CIP4 proteins were detected using a mouse anti-CIP4 antibody against human CIP4 aa 411--501. (Rat and human CIP4 are 92% identical.) **B**. Immunocytochemistry for α-actinin (green), ANF (red) and Hoechst (blue); bar = 20 μm. **C**. Cross-section area of myocytes. *n* = 7. **D**. Fraction of myocytes expressing ANF. *n* = 6. ANOVA (two-factor with replication): *p*-value (among the four CIP4 expression conditions) = 0.005 (C) and = 0.02 (D); *p*-value (±PE) \< 10^-6^ for both B and C. Post-hoc testing: ^\*^*p*-values vs. CIP4 siRNA-transfected myocytes; ^†^*p*-values comparing myocytes cultured ± PE; ^‡^*p*-values vs. myc-CIP4 WT expressing myocytes.](1423-0127-21-45-1){#F1}

Corrected Figure four (Figure [1](#F1){ref-type="fig"} here):
